Recro Pharma, Inc. (NASDAQ:REPH) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a report released on Tuesday, October 31st.
According to Zacks, “Recro Pharma, Inc. is a clinical stage specialty pharmaceutical company. It develops non-opioid therapeutics for the treatment of pain in the post-operative setting. The company is developing intranasal formulation of Dexmedetomidine (Dex) for the treatment of post-operative pain and cancer breakthrough pain; sublingual formulation of Dex for the treatment of chronic pain; and Fadolmidine (Fado), a product candidate to treat post-operative pain and neuropathic pain. Recro Pharma, Inc. is based in Malvern, Pennsylvania. “
A number of other research firms have also weighed in on REPH. Piper Jaffray Companies restated a “buy” rating and issued a $11.00 target price on shares of Recro Pharma in a report on Friday, October 27th. Roth Capital set a $20.00 price target on Recro Pharma and gave the company a “buy” rating in a research report on Monday, July 31st. Two investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The company currently has a consensus rating of “Buy” and an average target price of $12.63.
Shares of Recro Pharma (REPH) traded up $0.01 during mid-day trading on Tuesday, hitting $8.75. The stock had a trading volume of 42,600 shares, compared to its average volume of 118,921. The company has a quick ratio of 1.35, a current ratio of 1.59 and a debt-to-equity ratio of 0.50. Recro Pharma has a 12 month low of $5.81 and a 12 month high of $10.17.
Recro Pharma (NASDAQ:REPH) last announced its earnings results on Thursday, August 10th. The specialty pharmaceutical company reported ($0.48) EPS for the quarter, beating the consensus estimate of ($0.54) by $0.06. The company had revenue of $16.93 million for the quarter, compared to analyst estimates of $14.90 million. Recro Pharma had a negative return on equity of 60.01% and a negative net margin of 51.88%. research analysts predict that Recro Pharma will post -2.35 earnings per share for the current year.
COPYRIGHT VIOLATION NOTICE: “Recro Pharma, Inc. (NASDAQ:REPH) Lifted to Hold at Zacks Investment Research” was first reported by BBNS and is the sole property of of BBNS. If you are reading this story on another publication, it was copied illegally and reposted in violation of U.S. and international trademark and copyright law. The original version of this story can be read at https://baseballnewssource.com/markets/recro-pharma-inc-reph-stock-rating-upgraded-by-zacks-investment-research/1746844.html.
Hedge funds and other institutional investors have recently made changes to their positions in the company. Wells Fargo & Company MN boosted its stake in Recro Pharma by 3.0% during the first quarter. Wells Fargo & Company MN now owns 17,200 shares of the specialty pharmaceutical company’s stock valued at $150,000 after buying an additional 500 shares during the period. Bank of New York Mellon Corp bought a new stake in Recro Pharma during the first quarter valued at $156,000. KCG Holdings Inc. bought a new stake in Recro Pharma during the first quarter valued at $173,000. Rothschild Investment Corp IL bought a new stake in Recro Pharma during the second quarter valued at $141,000. Finally, JPMorgan Chase & Co. boosted its stake in Recro Pharma by 183.4% during the third quarter. JPMorgan Chase & Co. now owns 21,784 shares of the specialty pharmaceutical company’s stock valued at $197,000 after buying an additional 14,098 shares during the period. Institutional investors own 65.27% of the company’s stock.
About Recro Pharma
Recro Pharma, Inc is a clinical-stage specialty pharmaceutical company. The Company is engaged in developing products for hospitals and ambulatory care settings that is developing non-opioid products for treatment of serious acute pain. The Company’s lead product candidate is an injectable form of meloxicam.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Recro Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recro Pharma Inc. and related companies with our FREE daily email newsletter.